版本:
中国

BRIEF-Trillium expands clinical trial with TTI-621

June 7 Trillium Therapeutics Inc

* Trillium expands clinical trial with tti-621 to include combination with pd-1 blockade

* Trillium therapeutics inc - ‍further expanded its current intravenous dosing trial of tti-621, an igg1 sirpafc fusion protein targeting cd47​

* Trillium therapeutics inc - ‍changes to trial include increasing size of cohorts exhibiting early evidence of clinical benefit, among others​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐